CClinicalTrials.gg
Not yet recruitingNCT06318195CiPEUpdated Jul 10, 2024

Condensed Digital Prolonged Exposure for Individuals Treated Within Somatic Trauma Care.

An interventional study of Condensed Internet delivered prolonged exposure (CIPE) in Post Traumatic Stress Disorder and Acute Stress Disorder, sponsored by Karolinska Institutet. Not yet recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-10.

Sponsored by Karolinska Institutet · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Feb 2026, 8 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the study is to investigate the feasibility of implementation aspects, treatment effects and change processes regarding a brief trauma-focused Internet-based CBT treatment, for patients who have been treated in trauma care at Karolinska University Hospital and who exhibit symptoms of psychological consequences of the traumatic event. Another aim is to explore factors (predictors, moderators and mediators) that influence the effect of the treatment, in order to better understand who responds to the treatment.

Read the detailed description

The study is un-controlled with 250 participants that will undergo a brief trauma-focused Internet-based CBT treatment, delivered as a three-week treatment comprising of four modules (psychoeducation/rational, in vivo exposure, imaginal exposure and relapse prevention). The primary outcome is the PCL-5. Secondary outcomes are level of depression (PHQ-9), quality of life (WSAS) and predictors, moderators and mediators of clinically meaningful change in symptoms, dropout rate, rates of inclusion, attrition, adherence,and negative effects.

Self-reported, qualitative data from participants will be gathered at treatment completion to capture participants' experiences of participating in the intervention, as well as their views on how to further improve the intervention. The treatment effects will be evaluated using a within-group design with repeated measurements. Participants in the study will be will recruited from patients treated in the somatic trauma care at the Karolinska University Hospital in Stockholm, Sweden.

02

Conditions studied

  • Post Traumatic Stress Disorder
  • Acute Stress Disorder

Keywords

  • condensed prolonged exposure
  • Internet-delivered
  • PTSD
  • trauma
  • early intervention
  • prevention
  • CIPE
03

In context

Stress Disorders, Traumatic

1,147 studies on the registry are indexed under Stress Disorders, Traumatic; 108 are open to participants now.

This study's planned enrollment of 250 is above the median of 60 across 908 interventional studies indexed under Stress Disorders, Traumatic.

Browse Stress Disorders, Traumatic studies →

Lead sponsor

Karolinska Institutet is the lead sponsor of 1,113 studies on the registry; 267 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Exposed to trauma in the past two months according to criterion A for PTSD in the DSM-5 (exposed to death, threatened death, actual or threatened serious injury, or actual or threatened sexual violence).
  • PCL-5 total sum score>10
  • ≥ 18 years
  • Situated in Sweden
  • Signed informed consent

Exclusion criteria

Exclusion Criteria:

  • Other serious comorbidity as primary concern (ongoing substance dependence, untreated bipolar disorder, psychotic symptoms, severe depression, borderline personality disorder, high suicidal risk according to the MINI)
  • Unable to read and write in Swedish
  • Receiving other psychological trauma-focused treatment
  • Ongoing trauma-related threat (e.g., living with a violent spouse)
  • Not stable dose of antidepressant medication the last two weeks
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Condensed Internet delivered prolonged exposure (CIPE)

    Condensed Internet delivered prolonged exposure (CIPE) for three weeks with therapist support.

    Behavioral: Condensed Internet delivered prolonged exposure (CIPE)

Interventions

  • BehavioralCondensed Internet delivered prolonged exposure (CIPE)

    Condensed Internet delivered prolonged exposure (CIPE) with therapist support for three weeks.

06

What researchers measure

Primary outcomes

  1. Change in PTSD symptoms as assessed by the PTSD Check List - DSM-5 (PCL-5)

    The PCL-5 is a 20-item self-report measure based upon the Diagnostic and Statistical Manual (DSM-5) criteria for PTSD. Total Score (Range 0-80 with higher scores representing more PTSD symptoms.

    Time frame: week -3, -2 and -1 before treatment start, immediately before start of treatment, weekly through three weeks of treatment, post-treatment (immediately after treatment completion at three weeks), and the 1 month and 6 months follow up.

Secondary outcomes

  1. Change in depressive symptoms as measured by the Patient Health Questionnaire-9 (PHQ-9)

    The PHQ-9 is a widely used and well-validated instrument for measuring the severity of depressive symptoms. Scores are calculated based on how frequently a person experiences 9 symptoms of depression ranging from "not at all" response is scored as 0; "several days" response is 1; "more than half the days" response is 2; and "nearly every day" response is 3. Higher scores represents more depressive symptoms.

    Time frame: week -3 before treatment start, immediately before start of treatment, weekly through three weeks of treatment, post-treatment (immediately after treatment completion at three weeks), and the 1 month and 6 months follow up.

  2. Change in psychosocial impairment measured by The Work and Social Adjustment Scale (WSAS), adapted to symptoms of post-traumatic stress.

    WSAS is a short, self-reported instrument consisting of five items about psychosocial impairments rated on a nine-point Likert scale. A higher score means more severe impairment.

    Time frame: week -3 before treatment start, immediately before start of treatment, , weekly through three weeks of treatment, post-treatment (immediately after treatment completion at three weeks), and the 1 month and 6 months follow up.

Other outcomes

  1. Participants satisfaction with treatment.

    Qualitative questions pertaining participants satisfaction with the treatment.

    Time frame: Immediately after treatment completion.

  2. Adverse events related to treatment.

    Adverse events related to treatment measured by with a free text option where participant is instructed to describe the possible event in detail. If the participant reported any adverse event, additional follow-up questions about intensity, duration etc. will also be given.

    Time frame: Immediately after treatment completion.

  3. Number of completed treatment modules

    Data will be gathered on total number of completed modules during the three week treatment.

    Time frame: Baseline up to 3 weeks

  4. Number of messages sent and received in the digital platform

    Data will be gathered on total number of messages sent and received in the digital platform during the three week treatment.

    Time frame: Baseline up to 3 weeks

  5. Number of completed home work assignments by the participant during the treatment period

    Data will be gathered on total number of completed home work assignments by the participant during the three week treatment.

    Time frame: Baseline up to 3 weeks

  6. The proportion of participants that conducts the weekly measures and further assessment points

    The proportion of participants that conducts the weekly measures and further assessment points

    Time frame: Baseline up to 6 months

  7. The proportion of participants that go through the entire treatment period

    The proportion of participants that go through the entire treatment period

    Time frame: Baseline up to three weeks

  8. Number of drop-outs from treatment

    Number of drop-outs from treatment

    Time frame: Baseline up to three weeks

  9. Rates of inclusion to the study

    Data on rates of inclusion will be considered as an indication of the feasibility of the intervention.

    Time frame: Baseline

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06318195
Lead sponsor
Karolinska Institutet
Collaborators
Karolinska Universitetssjukhuset
Responsible party
Maria Bragesjo (PhD, Licensed Psychologist, Karolinska Institutet) — Principal investigator
First posted
Mar 19, 2024
Start date
Sep 2024 (estimated)
Primary completion
Feb 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
Jul 10, 2024

Study contacts

Maria Bragesjö, PhD
Contact
maria.bragesjo@ki.se
+46703399387
Maria Bragesjö, PhD
principal investigator · Karolinska Institutet

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion